Clinical Research Directory
Browse clinical research sites, groups, and studies.
BCMA-CD19 cCAR in Multiple Myeloma and Plasmacytoid Lymphoma
Sponsor: iCell Gene Therapeutics
Summary
This is a phase I, interventional, single arm, open label, treatment study to evaluate the safety and tolerability of BCMA-CD19 cCAR in patients with relapsed and/or refractory multiple myeloma and plasmacytoid lymphoma.
Official title: BCMA-CD19 cCAR in Relapsed and /or Refractory Multiple Myeloma and Plasmacytoid Lymphoma
Key Details
Gender
All
Age Range
Any - Any
Study Type
INTERVENTIONAL
Enrollment
12
Start Date
2019-07-01
Completion Date
2026-07
Last Updated
2025-09-16
Healthy Volunteers
No
Interventions
BCMA-CD19 cCAR T cells
BCMA-CD19 cCAR T cells administered to patients, will be either fresh or thawed CAR T cells by IV injection after receiving lymphodepleting chemotherapy
Locations (2)
Peking University Shenzhen Hospital, China
Shenzhen, Guangdong, China
Chengdu Military General Hospital
Chengdu, Sichuan, China